Premium
Macrophage inflammatory protein‐1α expression plasmid enhances DNA vaccine‐induced immune responses against HSV‐2
Author(s) -
Shao Wenai,
Li Xiaomian,
Li Mei,
Shi Liying,
Qin Yu,
Li Kangsheng
Publication year - 2005
Publication title -
immunology and cell biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.999
H-Index - 104
eISSN - 1440-1711
pISSN - 0818-9641
DOI - 10.1111/j.1440-1711.2005.01380.x
Subject(s) - dna vaccination , adjuvant , immune system , complementary dna , secretion , immunology , antibody , biology , medicine , microbiology and biotechnology , virology , immunization , gene , biochemistry
In this study, we examined the effectiveness of macrophage inflammatory protein (MIP)‐1α cDNA as a HSV‐2 DNA vaccine adjuvant. pcDNA3‐gD (pgD) and pcDNA3‐MIP‐1α (pMIP‐1α) were co‐injected to examine the modulatory effects of MIP‐1α on immune phenotype and protection against lethal challenge with HSV‐2. We found that Th‐cell proliferative responses were dramatically enhanced by co‐injection of pgD and pMIP‐1α compared with injection of pgD alone. The secretion of IL‐2 and IFN‐γ was also significantly increased by pgD and pMIP‐1α co‐injection; however, the production of cytokines IL‐4 and IL‐10 was not affected by co‐injection. pgD and pMIP‐1α co‐injection resulted in a moderate enhancement of systemic gD‐specific antibody level, but mucosal secretory IgA was markedly enhanced. When BALB/c mice were challenged intravaginally with 100 LD 50 of HSV‐2 strain Sav, pMIP‐1α co‐injection with pgD improved their survival rate and significantly reduced both the number of mice with lesions and the lesion severity. Therefore, MIP‐1α cDNA as a HSV‐2 DNA vaccine adjuvant drives antigen‐specific Th1‐type responses, reducing HSV‐2‐derived morbidity and mortality.